The Medicines Company announced the sequential release of topline data readouts upon completion of ORION-11, ORION-9 and ORION-10 is expected to start in the second half of the third quarter. The Company plans to prepare Phase 3 clinical data for scientific exchange at medical congresses and in peer-reviewed journals. In line with that expectation, the Company submitted a promissory abstract for a late-breaking science session at the European Society of Cardiology’s ESC Congress 2019, Paris, August 31 – September 4, to present efficacy, tolerability and safety data from ORION-11. The Independent Data Monitoring Committee (IDMC) for inclisiran’s pivotal Phase 3 trials (ORION-9, ORION-10 and ORION-11) recently completed its seventh planned review of un-blinded safety and efficacy data. The committee again recommended that the trials continue without modification. Ongoing review of blinded data to date from the Phase 3 trials shows no material safety issues, and the emerging data are at least as favorable as those generated from the ORION-1 Phase 2 and the ORION-3 open label extension studies.